	US 12,084,507 B2
	Humanized anti-NGF antibodies and methods of treating pain thereof
Sebastian C. J. Steiniger, Kalamazoo, MI (US); William Dunkle, Kalamazoo, MI (US); Catherine Rugg, Cronulla (AU); and Steven A. Dunham, Kalamazoo, MI (US)
Assigned to Zoetis Services LLC, Parsippany, NJ (US)
Filed by Zoetis Services LLC, Parsippany, NJ (US)
Filed on Mar. 10, 2021, as Appl. No. 17/197,358.
Application 17/197,358 is a division of application No. 16/251,293, filed on Jan. 18, 2019, granted, now 10,982,002.
Claims priority of provisional application 62/641,538, filed on Mar. 12, 2018.
Prior Publication US 2021/0198373 A1, Jul. 1, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 31/713 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61P 9/10 (2006.01); A61P 29/02 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); C12N 15/11 (2006.01); C12N 15/63 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2875 (2013.01) [A61K 31/713 (2013.01); A61K 39/39533 (2013.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01); A61P 9/10 (2018.01); A61P 29/02 (2018.01); C07K 16/22 (2013.01); C12N 15/11 (2013.01); C12N 15/63 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/30 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

8 Claims

1. A recombinant humanized antibody that specifically binds to Nerve Growth Factor (NGF) comprising:

a) a variable light chain comprising an amino acid sequence comprising the amino acid sequences selected from the group consisting of: SEQ ID NO:87, SEQ ID NO:89, and SEQ ID NO:91, and

b) a variable heavy chain comprising an amino acid sequence comprising the amino acid sequences selected from the group consisting of: SEQ ID NO:75, and SEQ ID NO:79.